Market Cap | 35.58M | P/E | - | EPS this Y | 32.30% | Ern Qtrly Grth | - |
Income | -38.72M | Forward P/E | -1.40 | EPS next Y | 43.20% | 50D Avg Chg | 1.00% |
Sales | - | PEG | -0.01 | EPS past 5Y | - | 200D Avg Chg | 10.00% |
Dividend | N/A | Price/Book | 1.49 | EPS next 5Y | 40.90% | 52W High Chg | -73.00% |
Recommedations | 1.50 | Quick Ratio | 2.84 | Shares Outstanding | 5.48M | 52W Low Chg | 327.00% |
Insider Own | 5.14% | ROA | -40.25% | Shares Float | 2.79M | Beta | -2.12 |
Inst Own | 47.75% | ROE | -248.11% | Shares Shorted/Prior | 21.64K/31.11K | Price | 15.15 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 81,293 | Target Price | 15.00 |
Oper. Margin | - | Earnings Date | Nov 11 | Volume | 123,403 | Change | 2.57% |
KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Oppenheimer | Outperform | Aug 19, 24 |
HC Wainwright & Co. | Buy | May 17, 24 |
HC Wainwright & Co. | Buy | Apr 2, 24 |
Oppenheimer | Outperform | Apr 1, 24 |
HC Wainwright & Co. | Buy | Nov 17, 23 |
HC Wainwright & Co. | Buy | Aug 11, 23 |
HC Wainwright & Co. | Buy | May 10, 23 |
HC Wainwright & Co. | Buy | May 1, 23 |
HC Wainwright & Co. | Buy | Apr 12, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Trachtenberg Eric | SEE REMARKS SEE REMARKS | Jan 04 | Sell | 28.55 | 60 | 1,713 | 11,495 | 01/06/23 |
Reumuth Mary | CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER | Jan 04 | Sell | 28.54 | 60 | 1,712 | 11,883 | 01/06/23 |
Brazzell Romulus K | SEE REMARKS SEE REMARKS | Jan 04 | Sell | 28.53 | 73 | 2,083 | 18,536 | 01/06/23 |
Bazemore Todd | SEE REMARKS SEE REMARKS | Jan 04 | Sell | 28.54 | 62 | 1,769 | 14,835 | 01/06/23 |
Iwicki Mark T | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Jan 04 | Sell | 28.54 | 198 | 5,651 | 45,966 | 01/06/23 |
Trachtenberg Eric | SEE REMARKS SEE REMARKS | Jun 27 | Sell | 0.37 | 2,613 | 967 | 111,203 | 06/29/22 |
Reumuth Mary | CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER | Jun 27 | Sell | 0.37 | 2,613 | 967 | 130,595 | 06/29/22 |
Brazzell Romulus K | SEE REMARKS SEE REMARKS | Jun 27 | Sell | 0.37 | 3,144 | 1,163 | 285,201 | 06/29/22 |
Bazemore Todd | SEE REMARKS SEE REMARKS | Jun 27 | Sell | 0.37 | 3,092 | 1,144 | 115,499 | 06/29/22 |
Iwicki Mark T | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Jun 27 | Sell | 0.37 | 7,975 | 2,951 | 251,183 | 06/29/22 |
RA CAPITAL MANAGEMENT, L.P. | 10% Owner 10% Owner | May 26 | Sell | 0.3636 | 1,005,686 | 365,667 | 7,039,613 | 05/26/22 |
RA CAPITAL MANAGEMENT, L.P. | 10% Owner 10% Owner | May 23 | Sell | 0.53 | 2,829,314 | 1,499,536 | 8,045,299 | 05/25/22 |
Chen Hongming | CHIEF SCIENTIFIC OFF.. CHIEF SCIENTIFIC OFFICER | Oct 26 | Sell | 1.81 | 30,500 | 55,205 | 204,515 | 10/28/21 |